Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium

The clinical implications of hypertension in addition to a high prevalence of both uncontrolled blood pressure and medication nonadherence promote interest in developing device-based approaches to hypertension treatment. The expansion of device-based therapies and ongoing clinical trials underscores the need for consistency in trial design, conduct, and definitions of clinical study elements to permit trial comparability and data poolability. Standardizing methods of blood pressure assessment, effectiveness measures beyond blood pressure alone, and safety outcomes are paramount. The Hypertension Academic Research Consortium (HARC) document represents an integration of evolving evidence and consensus opinion among leading experts in cardiovascular medicine and hypertension research with regulatory perspectives on clinical trial design and methodology. The HARC document integrates the collective information among device-based therapies for hypertension to better address existing challenges and identify unmet needs for technologies proposed to treat the world’s leading cause of death and disability. Consistent with the Academic Research Consortium charter, this document proposes pragmatic consensus clinical design principles and outcomes definitions for studies aimed at evaluating device-based hypertension therapies.

[1]  M. Middeke,et al.  Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.

[2]  K. Kario,et al.  Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. , 2021, Journal of the American College of Cardiology.

[3]  P. Neužil,et al.  Pacemaker‐Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study , 2021, Journal of the American Heart Association.

[4]  R. Townsend,et al.  Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF , 2021, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  M. Uder,et al.  Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial , 2021, The Lancet.

[6]  S. Pocock,et al.  Changes in Plasma Renin Activity after Renal Artery Sympathetic Denervation. , 2021, Journal of the American College of Cardiology.

[7]  Dave L Dixon,et al.  Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. , 2021, Journal of the American College of Cardiology.

[8]  G. Parati,et al.  2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. , 2021, Journal of hypertension.

[9]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[10]  S. Pocock,et al.  Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  Deepak L. Bhatt,et al.  Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. , 2020, Hypertension.

[12]  Baofeng Yang,et al.  Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension , 2020, Journal of the American Heart Association.

[13]  Byron C. Jaeger,et al.  Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. , 2020, JAMA.

[14]  R. Schmieder,et al.  Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension , 2020, Journal of hypertension.

[15]  E. Edelman,et al.  Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. , 2020, European heart journal.

[16]  R. Whitbourn,et al.  Renal Denervation in High-Risk Patients With Hypertension. , 2020, Journal of the American College of Cardiology.

[17]  G. Mancia,et al.  Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation , 2020 .

[18]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.

[19]  M. Böhm,et al.  Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. , 2020, Journal of hypertension.

[20]  Manesh R. Patel,et al.  Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial , 2020, The Lancet.

[21]  G. Chatellier,et al.  Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies , 2020, European heart journal.

[22]  C. Lücke,et al.  Changes in Stroke Volume After Renal Denervation , 2020, Hypertension.

[23]  K. Kario,et al.  Seasonal variation in blood pressure: Evidence, consensus and recommendations for clinical practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. , 2020, Journal of hypertension.

[24]  A. Bhowmik,et al.  Trial Randomised controlled trial , 2020 .

[25]  G. Molenberghs,et al.  Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints , 2019, Statistics in medicine.

[26]  Yaiza Beatriz Molero-Díez,et al.  Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.

[27]  K. Kario,et al.  Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy , 2019, Hypertension.

[28]  H. Thiele,et al.  Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies. , 2019, Hypertension.

[29]  A. Kirtane,et al.  Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. , 2019, Circulation.

[30]  Jonathan H Seltzer,et al.  Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. , 2019, JACC. Cardiovascular interventions.

[31]  Jackson T. Wright,et al.  Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. , 2019, Hypertension.

[32]  S. Pocock,et al.  Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial , 2019, European heart journal.

[33]  M. James,et al.  Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis. , 2019, The Canadian journal of cardiology.

[34]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[35]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[36]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[37]  J. Spertus,et al.  Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, European heart journal.

[38]  S. Pocock,et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.

[39]  Neil Chapman,et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.

[40]  Jeffrey N. Browndyke,et al.  Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative , 2018, European heart journal.

[41]  C. Tsioufis,et al.  Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis , 2018, Journal of hypertension.

[42]  J. Staessen,et al.  Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis. , 2018, Journal of hypertension.

[43]  C. Ott,et al.  Renal denervation improves 24‐hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance , 2018, Journal of clinical hypertension.

[44]  Daniel W. Jones,et al.  Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline , 2018, Circulation.

[45]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[46]  G. Stone,et al.  Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study , 2017, The Lancet.

[47]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[48]  N. Samani,et al.  Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence , 2017, Hypertension.

[49]  J. Gladman,et al.  Withdrawal of antihypertensive medication: a systematic review , 2017, Journal of hypertension.

[50]  G. Mancia,et al.  Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry , 2017, Journal of clinical hypertension.

[51]  Jeffrey N. Browndyke,et al.  Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. , 2017, Journal of the American College of Cardiology.

[52]  Deepak L. Bhatt,et al.  Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry , 2016, European heart journal.

[53]  Deepak L. Bhatt,et al.  Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. , 2016, Journal of the American College of Cardiology.

[54]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[55]  R. Townsend,et al.  Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. , 2016, Journal of the American Society of Hypertension : JASH.

[56]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[57]  M. Uder,et al.  Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension , 2015, Journal of hypertension.

[58]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[59]  E. Vink,et al.  Denervation of the Renal Arteries in Metabolic Syndrome: The DREAMS-Study , 2015, Hypertension.

[60]  G. Mancia,et al.  Clinical value of ambulatory blood pressure: evidence and limits. , 2015, Circulation research.

[61]  G. Grassi,et al.  Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy , 2015, Journal of hypertension.

[62]  I. Meredith,et al.  Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[63]  H. Krum,et al.  Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials: Implications for Trials of Renal Denervation , 2015, Hypertension.

[64]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[65]  Deepak L. Bhatt,et al.  Non-adherence to cardiovascular medications. , 2014, European heart journal.

[66]  B. Egan,et al.  Hypertension in the United States, 1999 to 2012: Progress Toward Healthy People 2020 Goals , 2014, Circulation.

[67]  R. Brook,et al.  A review of blood pressure measurement protocols among hypertension trials: implications for "evidence-based" clinical practice. , 2014, Journal of the American Society of Hypertension : JASH.

[68]  E. Wellnhofer,et al.  Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. , 2014, European heart journal.

[69]  Geoffrey A Head,et al.  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. , 2014, Journal of hypertension.

[70]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[71]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[72]  H. Krum,et al.  Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. , 2013, International journal of cardiology.

[73]  M. Böhm,et al.  Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. , 2013, International journal of cardiology.

[74]  C. Tsioufis,et al.  Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial , 2013, European heart journal.

[75]  Gianfranco Parati,et al.  Assessment and management of blood-pressure variability , 2013, Nature Reviews Cardiology.

[76]  A. Hughes,et al.  First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. , 2013, International journal of cardiology.

[77]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[78]  Dominik Linz,et al.  Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2012, Hypertension.

[79]  M. Böhm,et al.  Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.

[80]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, European heart journal.

[81]  M. Krucoff,et al.  The academic research consortium governance charter. , 2011, JACC. Cardiovascular interventions.

[82]  R. Agarwal,et al.  Home Blood Pressure Monitoring: How Good a Predictor of Long-Term Risk? , 2011, Current hypertension reports.

[83]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[84]  Jens Jordan,et al.  Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.

[85]  I. Hajjar,et al.  A novel measurement index for antihypertensive medication burden and its use. , 2009, Hypertension.

[86]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[87]  J. Ménard,et al.  Teletransmission of home blood pressure monitoring: making it easier. , 2008, Journal of hypertension.

[88]  G. Mancia,et al.  Neurogenic Abnormalities in Masked Hypertension , 2007, Hypertension.

[89]  Alice Stanton,et al.  Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality: The Dublin Outcome Study , 2005, Hypertension.

[90]  Roberto Sega,et al.  Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study , 2005, Circulation.

[91]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[92]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[93]  Paul A. Smith,et al.  Sympathetic neural mechanisms in white-coat hypertension. , 2002, Journal of the American College of Cardiology.

[94]  Gianfranco Parati,et al.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .

[95]  G Parati,et al.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. , 1999, JAMA.

[96]  F. Abboud,et al.  Sympathetic neural mechanisms in obstructive sleep apnea. , 1995, The Journal of clinical investigation.